HACKENSACK, N.J.--(BUSINESS WIRE)--Amorcyte, Inc. (Amorcyte), a privately funded biotechnology company developing cell therapy products to treat cardiovascular disease, announced today the completion of the second of four dose cohorts in its phase I clinical trial.
